S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00624
Abstract: The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to quickly react to the immense challenge presented to the world. The orally available 3CL protease inhibitor S-217622 is currently progressing through clinical trials… read more here.
Keywords: 3cl protease; protease inhibitor; 217622 3cl; inhibitor clinical ... See more keywords